What is Retatrutide and how is it different?

Retatrutide is a novel triple hormone receptor agonist developed by Eli Lilly that activates GLP-1, GIP, and glucagon receptors simultaneously. Early phase 2 trials showed unprecedented weight loss results of up to 24% body weight reduction - higher than any currently approved obesity medication. The triple mechanism enhances fat oxidation while preserving muscle mass better than dual or single agonists. Retatrutide is still in clinical trials and not yet FDA approved, but represents the next generation of obesity pharmacotherapy. If approved, it would become the most potent weight loss medication available.